• LIVING WITH CRC

    Machine learning model predicts severe neuropathy risk in CRC patients with diabetes receiving oxaliplatin

    An XGBoost model achieved an AUC of 0.880 in predicting dose-limiting toxicity among 513 CRC patients with diabetic peripheral neuropathy, identifying cumulative oxaliplatin dose, poor glycemic control (HbA1c > 8.0%), and systemic inflammation as key risk factors. (Journal of Visualized Experiments)